Advanced Search

Study Preview



Study Title and Description

Oligofructose-enriched inulin improves some inflammatory markers and metabolic endotoxemia in women with type 2 diabetes mellitus: a randomized controlled clinical trial.



Key Questions Addressed
1 Is this a fiber intervention study?
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Oligofructose-enriched inulin improves some inflammatory markers and metabolic endotoxemia in women with type 2 diabetes mellitus: a randomized controlled clinical trial.
Author Dehghan P., Pourghassem Gargari B., Asghari Jafar-abadi M.
Country Student Research Center, Faculty of Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran.
Year 2014
Numbers Pubmed ID: 24332524

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Fiber Database
Arms
No arms have been defined in this extraction form.

Design Details
Question... Follow Up Answer Follow-up Answer
Year of Publication 2013
  • Comments Comments (
    0
    ) |
Country of Publication Iran, Islamic Republic Of
  • Comments Comments (
    0
    ) |
What was the study design? Randomized Controlled Trial (parallel)
  • Comments Comments (
    0
    ) |
Was the study blinded? triple blind
  • Comments Comments (
    0
    ) |
Study diet type Isocaloric/Maintenance
  • Comments Comments (
    0
    ) |
Level of feeding control for dietary intervention Food partially provided
  • Comments Comments (
    0
    ) |
Sample size 52
  • Comments Comments (
    0
    ) |
Is there a run-in period? No
  • Comments Comments (
    0
    ) |
Is there a washout period? Not applicable
  • Comments Comments (
    0
    ) |
Did the administered fiber dose change over the course of the study? No
  • Comments Comments (
    0
    ) |
What is the age of the population (categorical)? Adults (20+ Years)
  • Comments Comments (
    0
    ) |
Study population, mean age in years ~48.6
  • Comments Comments (
    0
    ) |
Study population, age range in years -
  • Comments Comments (
    0
    ) |
Study Population, mean BMI, kg/m2 ~30.9
  • Comments Comments (
    0
    ) |
Study population, BMI Range, kg/m2 25-35
  • Comments Comments (
    0
    ) |
Baseline health status Diabetes
  • Comments Comments (
    0
    ) |
Gender (% male) 0
  • Comments Comments (
    0
    ) |
Fiber 1-type Oligofructose-Enriched Inulin (Of-In)
  • Comments Comments (
    0
    ) |
Fiber 1-if combination was selected for fiber type, 1st fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 1-if combination was selected for fiber type, 2nd fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 1- dose 1 (g) 10
  • Comments Comments (
    0
    ) |
Fiber 1- dose 2 (g) -
  • Comments Comments (
    0
    ) |
Fiber 1-Duration of intervention 8 weeks
  • Comments Comments (
    0
    ) |
Fiber 1-how was the fiber administered? Unspecified
  • Comments Comments (
    0
    ) |
Fiber 2-type -
  • Comments Comments (
    0
    ) |
Fiber 2-if combination was selected for fiber type, 1st fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 2-if combination was selected for fiber type, 2nd fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 2- dose 1 (g) -
  • Comments Comments (
    0
    ) |
Fiber 2- dose 2 (g) -
  • Comments Comments (
    0
    ) |
Fiber 2-Duration of intervention -
  • Comments Comments (
    0
    ) |
Fiber 2-how was the fiber administered? -
  • Comments Comments (
    0
    ) |
Fiber 3-type -
  • Comments Comments (
    0
    ) |
Fiber 3-if combination was selected for fiber type, 1st fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 3-if combination was selected for fiber type, 2nd fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 3- dose 1 (g) -
  • Comments Comments (
    0
    ) |
Fiber 3- dose 2 (g) -
  • Comments Comments (
    0
    ) |
Fiber 3-Duration of intervention -
  • Comments Comments (
    0
    ) |
Fiber 3-how was the fiber administered? -
  • Comments Comments (
    0
    ) |
Fiber 4-type -
  • Comments Comments (
    0
    ) |
Fiber 4-if combination was selected for fiber type, 1st fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 4-if combination was selected for fiber type, 2nd fiber type in combination -
  • Comments Comments (
    0
    ) |
Fiber 4- dose 1 (g) -
  • Comments Comments (
    0
    ) |
Fiber 4- dose 2 (g) -
  • Comments Comments (
    0
    ) |
Fiber 4-Duration of intervention -
  • Comments Comments (
    0
    ) |
Fiber 4-how was the fiber administered? -
  • Comments Comments (
    0
    ) |
Comparator 1- what was the comparator used in the intervention? maltodextrin, 10g/d
  • Comments Comments (
    0
    ) |
Comparator 1-dose 0
  • Comments Comments (
    0
    ) |
Comparator 1-duration of comparator intervention 8 weeks
  • Comments Comments (
    0
    ) |
Comparator 1-how was the comparator administered to participants? Unspecified
  • Comments Comments (
    0
    ) |
Comparator 2- what was the comparator used in the intervention? -
  • Comments Comments (
    0
    ) |
Comparator 2-dose -
  • Comments Comments (
    0
    ) |
Comparator 2-duration of comparator intervention -
  • Comments Comments (
    0
    ) |
Comparator 2-how was the comparator administered to participants? -
  • Comments Comments (
    0
    ) |
Comparator 3- what was the comparator used in the intervention? -
  • Comments Comments (
    0
    ) |
Comparator 3-dose -
  • Comments Comments (
    0
    ) |
Comparator 3-duration of comparator intervention -
  • Comments Comments (
    0
    ) |
Comparator 3-how was the comparator administered to participants? -
  • Comments Comments (
    0
    ) |
Comparator 4- what was the comparator used in the intervention? -
  • Comments Comments (
    0
    ) |
Comparator 4-dose -
  • Comments Comments (
    0
    ) |
Comparator 4-duration of comparator intervention -
  • Comments Comments (
    0
    ) |
Comparator 4-how was the comparator administered to participants? -
  • Comments Comments (
    0
    ) |


Baseline Characteristics
No baseline characteristics have been defined for this extraction form.



Results & Comparisons

No Results found.
Adverse Events
Arm or Total Title Description Comments

Quality Dimensions
No quality dimensions were specified.

Quality Rating
No quality rating data was found.